Background: Cardiopulmonary bypass during cardiac surgery leads to impaired microcirculatory perfusion. We hypothesized that vascular leakage is an important contributor to microcirculatory dysfunction. Imatinib, a tyrosine kinase inhibitor, has been shown to reduce vascular leakage in septic mice. We investigated whether prevention of vascular leakage using imatinib preserves microcirculatory perfusion and reduces organ injury markers in a rat model of cardiopulmonary bypass. Methods: Male Wistar rats underwent cardiopulmonary bypass after treatment with imatinib or vehicle (n¼8 per group). Cremaster muscle microcirculatory perfusion and quadriceps microvascular oxygen saturation were measured using intravital microscopy and reflectance spectroscopy. Evans Blue extravasation was determined in separate experiments. Organ injury markers were determined in plasma, intestine, kidney, and lungs. Results: The onset of cardiopulmonary bypass decreased the number of perfused microvessels by 40% in the control group [9.4 (8.6e10.6) to 5.7 (4.8e6.2) per microscope field; P<0.001 vs baseline], whereas this reduction was not seen in the
imatinib group. In the control group, the number of perfused capillaries remained low throughout the experiment, whilst perfusion remained normal after imatinib administration. Microvascular oxygen saturation was less impaired after imatinib treatment compared with controls. Imatinib reduced vascular leakage and decreased fluid resuscitation compared with control [3 (3e6) vs 12 ml (7e16); P¼0.024]. Plasma neutrophil-gelatinase-associated-lipocalin concentrations were reduced by imatinib. Conclusions: Prevention of endothelial barrier dysfunction using imatinib preserved microcirculatory perfusion and oxygenation during and after cardiopulmonary bypass. Moreover, imatinib-induced protection of endothelial barrier integrity reduced fluid-resuscitation requirements and attenuated renal and pulmonary injury markers.
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Editor's key points
Cardiopulmonary bypass results in impaired microcirculatory perfusion. Imatinib reduces vascular leakage in animal sepsis models and may consequently improve microcirculatory perfusion. Intravital microscopy showed imatinib protected against loss of perfused capillaries and reduced microvascular oxygen saturation caused by cardiopulmonary bypass in a rat model. Renal and pulmonary injury markers were reduced by imatinib, and fluid-resuscitation requirements were reduced. Imatinib may benefit postoperative organ function in high-risk cardiac-surgery patients.
Microcirculatory perfusion is disturbed during cardiac surgery with cardiopulmonary bypass (CPB), 1e3 but the underlying mechanisms remain to be elucidated. We recently showed in a rat CPB model that inflammation and endothelial activation contribute more to these microcirculatory-perfusion disturbances than haemodilution. 3 Moreover, microcirculatory dysfunction was paralleled by increases in markers of renal injury, and renal and pulmonary endothelial activation. 3 Clinical studies and in vitro experiments using cultured endothelial cells show that endothelial activation and inflammation during CPB elicit endothelial barrier dysfunction with subsequent vascular leakage. 4e6 Moreover, vascular leakage is associated with postoperative pulmonary and renal dysfunction, 4, 5 which may be mediated by a reduction in capillary perfusion due to interstitial fluid accumulation. 7 Whilst the association of vascular leakage with impaired microcirculatory perfusion seems obvious, there is only one study showing that endothelial barrier dysfunction as a result of inhibition of platelet endothelial cell adhesion molecule-1 was paralleled by preserved capillary perfusion in a rat cremaster muscle ischaemiaereperfusion model. 8 Imatinib, an inhibitor of multiple tyrosine kinases, including c-KIT, platelet-derived growth factor receptor, c-Abl, and Abl-related gene (Arg), 9 prevents endothelial barrier dysfunction after inflammatory stimulation of an endothelial monolayer. It further reduces vascular leakage in animal models of sepsis and acute lung injury, attributed to blockade of the c-Abl and Arg pathways. 10, 11 These findings led to our hypothesis that vascular leakage is an important contributor to impaired microcirculatory perfusion during CPB, and that prevention of vascular leakage by imatinib might preserve microvascular perfusion and oxygenation via protection of endothelial integrity and barrier function. We additionally investigated whether the preservation of endothelial barrier function reduces soluble and histological markers for organ injury, and diminishes the consequences of systemic inflammation induced by CPB.
Methods

Animals
All experiments were approved by the Institutional Animal Care and Use Committee of the VU University Medical Center. The experiments were conducted following the EU Directive on the protection of animals used for scientific purposes (EU2010/63), the Dutch Animal Experimentation Act, and are reported in accordance with relevant aspects of the Animal Research: Reporting of In Vivo Experiments guidelines. Animals were housed four per cage with unrestricted access to food and water in a temperature-controlled room (20e23 C; 40e60% humidity) with a 12/12 h light/dark cycle. Animal care was undertaken according to the national guidelines for care of laboratory animals. A total of 24 male Wistar rats of 375e425 g (Charles River Laboratories, Brussels, Belgium) underwent CPB procedures. Sixteen rats were randomized to treatment with imatinib (CPB imatinib; n¼8) or saline (CPB control; n¼8) before CPB. All measurements were performed in these groups, except for vascular-leakage quantification. Vascular leakage was determined in separate experiments, in which eight additional rats were randomized to undergo CPB with (n¼4) or without imatinib (n¼4).
Anaesthesia and surgical preparation
Anaesthesia was induced as described previously. 3 Briefly, anaesthesia was induced with isoflurane 5% in oxygen, and when the pedal withdrawal response to a nociceptive stimulus was absent, tracheal intubation with a 16G catheter was performed (Venflon Pro; Becton Dickinson, Helsingborg, Sweden 
Rat cardiopulmonary bypass protocol
The CPB circuit consisted of a Plexiglas venous reservoir, a roller pump (Pericor SF70; Verder, Haan, Germany), and a 4 ml Plexiglas oxygenator heat exchanger (Ing. M. Humbs, Valley, Germany) with a three-layer hollow fibre membrane (Oxyphan; Membrana, Wuppertal, Germany) for gas exchange, as described previously. 3 Detailed information can be found in the Supplementary File.
Microcirculatory measurements
Intravital microcirculatory observation was performed on the cremaster muscle. 3 A 10Â objective (W N-Achroplan; Zeiss, Oberkochen, Germany; numerical aperture 0.30) on an intravital microscope (Axiotech Vario 100 HD; Zeiss) was connected to a digital camera (scA640; Basler, Ahrensburg, Germany). The final magnification was 640Â. At baseline, 12 regions of undisturbed tissue architecture and normal perfusion were selected for measurements. In each region, videos of 10e15 s were recorded at each time point, combining for 12 videos per time point. The location of each baseline video was noted according to vascular anatomy in order to monitor perfusion changes in the same capillaries. Baseline measurements were performed after a 30 min stabilisation period of the exposed cremaster muscle. Subsequent measurements were made at 10, 30, and 60 min of CPB, and 10 and 60 min after discontinuation of CPB, at the same locations as the baseline measurements. Microcirculatory-perfusion analyses were performed offline and the investigator was blinded to the allocated experimental group. As described previously, capillary crossings with two vertical test lines were counted per screen, and subdivided into perfused, intermittently perfused, and non-perfused capillaries, and microcirculatory heterogeneity was subsequently calculated using the coefficient of variation for each time point. 3, 12 In pilot CPB experiments,
Pearson coefficient of the inter-observer correlation of the number of perfused vessels was 0.919 (P<0.001). Microvascular haemoglobin oxygen saturation (mHbSO 2 ) was measured with reflectance spectroscopy (O2C; LEA Medizintechnik GmbH, Giessen, Germany) on the right quadriceps muscle. 13 White light (450e1000 nm) was illuminated by a microprobe, and reflected light was analysed for the absorption spectra of oxygenated and deoxygenated haemoglobin in the tissue. As vessels with a diameter larger than 100 mm completely absorb the emitted light, 14 the mHbSO 2 results reflect the haemoglobin oxygenation mainly in postcapillary venules. The probe was placed in the position that was considered the most stable, and thus, least prone to movement of the probe position, in order to avoid the influence of varying sample areas on the current data. Because of the considerable between-subject variability at baseline, the data were normalized to baseline for each subject.
Vascular leakage
Evans Blue dye extravasation was used for the analysis of vascular leakage, as described previously. 10 In 
Immunohistochemical analyses
The immunohistochemical analysis of renal paraffin sections stained with myeloperoxidase (MPO) and N(ε)-(carboxymethyl)lysine (CML) was performed, as described previously, 3 in order to assess the glomerular neutrophil infiltration and inflammatory status of the glomerular endothelium, respectively. Detailed information can be found in the Supplementary File.
mRNA expression analysis
Total RNA isolation from cryosections from renal, pulmonary, and intestinal tissue occurred, as described previously, 3 using the RNeasy Plus Mini Kit (QIAGEN, Leusden, The Netherlands) according to the manufacturer's instructions. Gel electrophoresis was used to determine the integrity of RNA, and yield and purity were measured with NanoDrop ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Rockland, DE, USA). RNA was reverse transcribed into cDNA using SuperScript III reverse transcriptase (Invitrogen, Breda, The Netherlands) and random hexamer primers (Promega, Leiden, The Netherlands). The following Assays-on-Demand primers (Applied Biosystems, Foster City, CA, USA) were used for mRNA analysis using polymerase chain reaction: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Eselectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), tumour necrosis factor-a (TNF-a), interleukin (IL)-6 (IL-6), IL-10, monocyte chemoattractant protein-1 (MCP-1), and MPO. The samples were assayed in duplicate and the obtained threshold cycle values (Ct) were averaged per sample. Subsequently, the average Ct value of the housekeeping gene GAPDH is subtracted from the average Ct value of the gene of interest, yielding the DCt value. The calculation of 2-DCt results in the relative mRNA expression level of the gene of interest, and was averaged per group.
Preparation of tissue homogenates
Cryostate sections from renal, pulmonary, and intestinal tissue were cut and lysed on ice in radioimmunoprecipitation assay buffer [50 mM Tris-HCl, pH 8.0; 150 mM NaCl; sodium deoxycholate 0.5% (w/v); SDS 0.1% (w/v); IGEPAL 1% (SigmaAldrich, St. Louis, MO, USA; v/v)] containing protease inhibitor cocktail (Roche Diagnostics, Almere, The Netherlands), phosphatase inhibitor (Roche), and activated 1 mM Na 3 VO 4 . Homogenates were sonicated two times for 5 s on ice and centrifuged for 10 min at 14 000 g at 4 C. The total protein concentrations in the supernatants were determined using a DC Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA).
Protein expression in tissue homogenates and plasma
Protein concentrations were measured using commercial enzyme immunoassay kits according to the manufacturer's instructions in tissue homogenates [TNF-a: BioLegend, London, UK; MCP-1 and IL-1 beta (IL-1b): R&D Systems, Abingdon, UK; and neutrophil gelatinase-associated lipocalin (NGAL): BioPorto, Hellerup, Denmark] and plasma (TNF-a, MCP-1, and IL-6: BioLegend; and NGAL and MPO: Hycult Biotech, Uden, The Netherlands). Inter-and intra-assay precision is specified in the Supplementary File. The obtained protein concentrations for tissue homogenates were corrected for the total protein input of tissue homogenate, and expressed as pg protein of interest per mg total protein content.
Electron microscopy
The intestinal tissue was used for the analysis of capillary endothelial ultrastructure, given the association of intestinal endothelial barrier dysfunction with the development of organ dysfunction. 1, 15 After fixation in buffered formaldehyde 4%, the intestinal tissue was postfixed in osmium tetroxide 1%. The tissue was then dehydrated through a graded series of ethanol resolutions of 70e95% and embedded in JB-4 Plus resin (Merck, Darmstadt, Germany). Thereafter, 0.5-to 3-mm-thick sections were cut with a glass knife. These semi-thin sections were processed for electron microscopy. A JEOL-1200EX (JEOL, Tokyo, Japan) electron microscope was used. Ten random capillaries captured in full cross section by an investigator blinded to group allocation were then analysed for signs of endothelial cell injury, including the number of luminal membrane blebs and vacuoles. 16, 17 Additionally, breaches in the luminal barrier formed by the endothelial cells were counted.
Statistical analysis
Data were analysed using an SPSS statistical software package (IBM, Armonk, NY, USA; version 20.0). All values are expressed as median with full range, unless specified otherwise. Sample size was calculated for the number of perfused capillaries, our primary outcome, and was based on a previous study, in which non-pulsatile CPB induced a maximal decrease in sublingual perfused capillaries from 18.9 (3.5; mean with standard deviation) to 13.2 mm mm À2 in humans. 2 Aiming to prevent this decrease with imatinib treatment and using an a of 0.05 and a power of 0.9, a sample size of eight per group was required. Time-dependent changes between groups were analysed using repeated measures (RM) analysis of variance (ANOVA). Two-sided ManneWhitney U-and Wilcoxon tests were used to evaluate the differences in-between groups and within groups, respectively. Post hoc Bonferroni correction was applied for parameters with repeated measurements. P<0.05 was considered as statistically significant.
Results
All animals completed the experimental protocol and were analysed on an intention-to-treat basis. The rats weighed 410 (394e425) and 403 g (390e410) for control and imatinib groups, respectively (P¼0.315).
Systemic variables
Imatinib did not alter the mean arterial pressure at baseline, whilst the mean arterial pressure decreased in both groups during CPB, and was augmented after disconnection from CPB (Fig. 1A) . The haematocrit levels decreased by 48% (P<0.001 vs baseline) in the control group and by 52% (P<0.001 vs baseline) in the imatinib group after onset of CPB (Fig. 1B ). There were no differences between groups in either blood pressure or haematocrit values during the course of the experiments. 
In vivo microcirculatory perfusion and oxygenation
The number of perfused capillaries in the cremaster muscle at baseline was similar between groups. In the control group, the number of perfused capillaries decreased by 39% (P<0.001 vs baseline) after the onset of CPB ( Fig. 2A) . In rats treated with imatinib, a non-significant temporary reduction of 7% in the number of perfused capillaries was observed (P¼0.054 vs baseline). At all time points during and after CPB, the number of perfused capillaries was higher after imatinib treatment than in the control group (ANOVA RM P¼0.007). Imatinib did not alter the number of non-perfused vessels at baseline. Both groups showed an increase in non-perfused vessels 10 min after the onset of CPB [control: 0.1 (0.0e0.6) to 1.1 (0.6e2.0) per microscope screen; P¼0.012; imatinib: 0.3 (0.3e0.5) to 0.7 (0.5e1.6) per microscope screen; P¼0.012). However, this increase in nonperfused vessels as compared with baseline was no longer detected in the subsequent time points in the imatinib group, whereas this elevation persisted in the control group throughout the experiment (Fig. 2B) . . At all time points during and after CPB, the microcirculatory heterogeneity was higher in the control group as compared with the imatinib group. Similar to the microcirculatory perfusion, the microcirculatory haemoglobin oxygen saturation was better preserved during CPB with imatinib treatment (Fig. 2C ). The control groups had a mHbSO 2 of 0.85 (0.63e0.86) and 0.79 (0.65e0.90) of baseline at 30 and 60 min of CPB, respectively, whereas this was 0.98 (0.90e1.02) and 1.02 (0.78e1.04) of baseline for the imatinib group (P¼0.11 and P¼0.028 between groups at 30 and 60 min of CPB, respectively).
Vascular leakage
The vascular-leakage rates in the hour after CPB with and without imatinib treatment are presented in Fig. 3AeC for renal, lung, and intestinal tissue, respectively. Intestinal and pulmonary extravasation after CPB was reduced with imatinib as compared with the control group, whereas no significant difference in renal vascular leakage between groups was detected.
The imatinib treatment reduced the need for fluid resuscitation during and after CPB by 75% compared with the control group [imatinib: 3 (3e6) ml vs control: 12 (7e16) ml; P¼0.024].
Renal immunohistology
The imatinib treatment reduced the glomerular neutrophil infiltration as compared with the control group (Fig. 4A) . Moreover, the glomerular endothelial CML intensity was significantly lower in the imatinib group than in the control group (Fig. 4D) .
Inflammatory cytokine and endothelial activation
The imatinib treatment decreased the pulmonary inflammation as demonstrated by reduced levels of pulmonary IL-1b, IL-6, TNF-a, and MCP-1 mRNA expression, and pulmonary IL-1b, TNF-a, and MCP-1 protein expression after CPB as compared with the control group (Table 1) . Similarly, the intestinal MCP-1 mRNA expression and protein concentrations and TNF-a mRNA expression were reduced by the imatinib treatment. The plasma concentrations of MCP-1 were reduced by the imatinib treatment as compared with control [32 (16e46) vs 46 (37e69) ng ml À1 , respectively; P¼0.005), but the plasma In vivo microcirculatory perfusion and oxygenation. Number of (A) perfused and (B) non-perfused capillaries assessed with cremaster muscle intravital microscopy and (C) microvascular haemoglobin oxygen saturation in the quadriceps muscle for the control group (white; n¼8) and the imatinib group (grey; n¼8 The imatinib treatment led to reduced pulmonary P-selectin mRNA expression after CPB (Table 1) . No differences in pulmonary VCAM-1 and ICAM-1 mRNA expression could be detected between groups, nor were there any differences in endothelial adhesion molecules in intestinal or renal tissue. 
Organ injury markers
Endothelial electron microscopy
The intestinal capillary endothelial ultrastructure was better preserved after CPB with imatinib in comparison with the control group (Fig. 5) 
Discussion
The current study demonstrates that a reduction in endothelial barrier dysfunction and vascular leakage using imatinib in rats undergoing CPB preserves the microcirculatory perfusion and oxygenation. This was associated with reduced fluidresuscitation requirements during and after CPB. The endothelial cell ultrastructure and endothelial barrier were better preserved in the imatinib group as compared with the control group. Additionally, we demonstrate that the imatinib treatment resulted in a reduction in endothelial activation and inflammation in the kidney, lung, and gastrointestinal system, paralleled by a decrease in renal and pulmonary injury markers. We are the first to show the important contribution of vascular leakage to the disturbances in microcirculatory perfusion during CPB. Our findings are an important step in revealing the pathogenesis underlying microcirculatory dysfunction in acute inflammatory activation. The impaired microcirculatory perfusion during CPB has been studied extensively, but the underlying mechanisms have remained unclear so far.
1,2 Microcirculatory disturbances frequently occur independent from alterations in macrocirculatory parameters. 2, 18, 19 We recently showed that haemodilution to a haematocrit of 24% led to a minor and temporary decrease in perfused capillaries, and could not fully explain microcirculatory impairment observed during CPB. 3 In contrast, pulsatile flow during CPB was associated with improved postoperative microvascular recovery, reduced vascular wall inflammation, and loss of glycocalyx integrity as compared with non-pulsatile flow. 2, 20, 21 This suggests a role for mechanotransduction in the preservation of endothelial function and subsequently microcirculatory perfusion. Fluid extravasation interferes with tissue oxygenation at two levels: extravascular compression of capillaries leads to decreased capillary perfusion 7 and an increased barrier for oxygen diffusion from the capillary to the cell. 12, 22 The impact of a Blue dye extravasation corrected for organ dry weight in the control group (white; n¼4) and the imatinib group (grey; n¼4). *P<0.05 between groups. CPB, cardiopulmonary bypass. Table 1 Cytokine and endothelial adhesion molecule mRNA expression and cytokine protein expression in organs. Renal, pulmonary, and intestinal inflammatory and endothelial activation for the control group (n¼8) and the imatinib group (n¼8), expressed as median (full range). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ICAM-1, intercellular adhesion molecule-1; IL-1b, interleukin-1 beta; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; TNF-a, tumour necrosis factor-a; VCAM-1, vascular cell adhesion molecule-1. disturbed balance between intracapillary and interstitial pressures and compromised microvascular perfusion was shown by Cabrales and colleagues. 23 In their hamster window chamber model, they showed that sufficient intracapillary pressure was required to maintain perfused capillary density during acute normovolaemic haemodilution. 23 Here, we show that prevention of vascular leakage preserves microcirculatory perfusion during CPB, supporting the important role for vascular leakage in the development of microvascular-perfusion disorders during CPB. As endothelial barrier dysfunction is seen in humans undergoing cardiac surgery with CPB, 4e6 this pathophysiological mechanism can be considered as a potential therapeutic target for the improvement of microcirculatory perfusion and reduction of organ injury in the clinical setting. Imatinib reduced the vascular leakage in the lung and intestines. Moreover, the intestinal capillary endothelial ultrastructure was less disturbed after CPB in imatinib-treated rats when compared with controls. In particular, imatinib reduces breaches in the endothelial barrier, and consequently, the area of direct contact of the capillary lumen with the capillary basement membrane that facilitates vascular leakage. Interestingly, fluid-resuscitation requirements during and after CPB were reduced by 75% by imatinib treatment when compared with untreated animals, irrespective of haematocrit and mean arterial pressure. Others showed that on-pump cardiac surgery induces endothelial barrier dysfunction 4e6 in association with a positive fluid balance, 5 suggesting perioperative vascular leakage. As fluid overload after cardiac surgery is an independent predictor of postoperative morbidity, 24 its burden may be reduced by interventions that preserve endothelial barrier function, as we show in the present study.
The association between impaired microcirculatory perfusion and poor clinical outcome has been observed for sepsis, cardiogenic shock, and abdominal surgery, 25e27 but not for cardiac surgery. However, the hypothesized role for microcirculatory-perfusion disturbances in the development of acute kidney injury (AKI) 28 or acute respiratory distress syndrome 29, 30 is supported by our findings. The imatinib treatment resulted in reduced renal glomerular endothelial inflammation and neutrophil deposition, and reduced plasma concentrations of NGAL, a marker of tubular damage and predictor of AKI. 31 AKI after CPB remains a multifactorial disease associated with increased mortality 32, 33 ; however, so far, advances in aetiology and therefore in rational pharmacological therapy are missing. 28, 34 Our results suggest that preservation of microvascular perfusion during CPB using imatinib is associated with reduced signs of injury and inflammation in the kidney, lung, and intestines, and this information may be used in treatment strategies for high-risk patients. Imatinib reduced the inflammatory and endothelial activation response in intestinal, pulmonary, and renal tissue, and in plasma. As both groups were exposed to equal CPB-induced inflammatory activation, 35 the difference in inflammatory activation markers is remarkable. The reduced inflammatory response and endothelial activation in the imatinib group may hypothetically be an effect secondary to preserved microvascular perfusion. Imatinib has, however, been associated with reduced inflammation in previous in vivo experimental investigations, 36 although this anti-inflammatory effect may only appear after prolonged exposure. 37 This direct antiinflammatory effect by imatinib was not investigated in the current study. A treatment combining anti-inflammatory and endothelial barrier protective effects may, however, be advantageous in on-pump cardiac surgery. 38 Moreover, imatinib is a registered drug for the treatment of chronic myeloid leukaemia, and extensive experience has already been generated with its use, making it a suitable candidate for further clinical investigation of its possible benefits on microvascular perfusion and organ function in on-pump cardiac surgery.
The current study has several limitations. Our current rat model is a beating-heart CPB model. However, it enabled conduct of total CPB with minimalized pulse pressure and discontinuation of ventilation during CPB without the occurrence of hypoxemia or cardiac complications. Moreover, all physiological alterations as they occur during human CPB (e.g. haemodilution, inflammatory activation, non-pulsatile flow, and mild hypothermia) are present in the current model, which makes its resemblance to the human setting relatively high. 39 It would be of interest to study the protein expression of IL-6 in lung, kidney, and intestines. Unfortunately, the assay kit did not show a linear response, and the analyses were interpreted as not reproducible.
Although the use of biomarkers for renal injury may be controversial, we did not expect the creatinine clearance to be a sensitive marker of renal injury within the short time course of our study. 40 We, therefore, used plasma NGAL concentrations as a renal injury marker, which had a good predictive value of AKI in adult cardiac surgical patients.
41
The extracorporeal circuit was primed with a colloid solution [hydroxyethyl starch (HES) 130/0.4], which may be controversial, in particular when investigating AKI. However, it has been shown that acute normovolaemic haemodilution using crystalloids is more deleterious for renal function and microvascular oxygenation as compared with colloids. 42 A prospective cohort study confirmed that the use of modern HES solutions was not associated with increased rates of AKI in a cardiac surgical population.
43
This study did not investigate by which pathway imatinib exerted its preserving effects on the endothelial barrier function. Multiple in vitro studies have, however, confirmed the importance of the Abl kinases c-Abl and Arg in the action of imatinib of endothelial barrier dysfunction, mostly in septic or endotoxemic models. 10, 11, 44 In thrombin-stimulated endothelial cell monolayers, Arg knockdown had similar effects as the imatinib treatment, whereas there were no addictive effects during the combined treatment. 10 In non-septic models, the pathway by which vascular leakage is reduced by imatinib is currently unknown. However, the activation of c-Abl and Arg pathways in septic models may occur through vascular endothelial growth factor or thrombin stimulation, or reduced sphingosine-1-phosphate activity, 36 all of which are activated during CPB-induced inflammation. 35, 45, 46 The role of the endothelial glycocalyx has not been investigated in the current study, although its contribution to endothelial barrier function is increasingly acknowledged. 47 Moreover, the endothelial glycocalyx dimensions are known to be compromised during on-pump cardiac surgery. 20 Although there is currently no evidence for a direct beneficial effect on the glycocalyx by imatinib, a possible role for the endothelial glycocalyx in the reduction of vascular leakage and the maintenance of capillary patency during CPB should be investigated.
In conclusion, our findings suggest that vascular leakage plays an important role in the development of impaired microcirculatory perfusion and oxygenation, and organ dysfunction after CPB. Moreover, the reduction of vascular leakage by imatinib treatment decreases the microcirculatory alterations and fluid-resuscitation requirements, 
